Chemomab Therapeutics Ltd expected to post a loss of 25  cents a share - Earnings Preview

Chemomab Therapeutics

10/08/2022 12:01

* Chemomab Therapeutics Ltd  CMMB.OQ   CMMB.O  is expected
to show
no change in quarterly revenue when it reports  results on
August 12. 
    * ​Refinitiv's mean analyst estimate for Chemomab
Therapeutics Ltd
is for a loss of 25 cents per share. For the same quarter last
year, the company reported a loss of 26 cents per share.
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 3 "strong buy" or "buy," no
"hold" and no "sell" or "strong sell."  
    * The mean earnings estimate of analysts was unchanged in
the last
three months. ​
    * Wall Street's median 12-month price target for Chemomab
Therapeutics Ltd is $21​, above​ its last closing price
of $3.50. ​​​
    * Previous quarterly performance (using preferred earnings
measure
in US dollars). ​

 QUARTER       STARMINESM  REFINITIV  ACTUAL    BEAT,   SURPRI
 ENDING        ARTESTIMAT  IBES                 MET,    SE %
               E®          ESTIMATE             MISSED  
 Mar. 31 2022  -0.47       -0.24      -0.44     Missed  -79.6
 Dec. 31 2022  -0.16       -0.10      -0.44     Missed  -325.8
 Sep. 30 2021              -0.14      -0.26     Missed  -79.3​
 Jun. 30 2021  -0.10       -0.11      -0.26     Missed  -126.1
 ​​Mar.        -0.43       -0.43      -0.22     Beat    48.8
 31 2021                                                
                                                        ​
 This summary was machine generated August 10 at 11:01 GMT.  All
figures in US dollars  unless otherwise stated